Different hormonal therapy approaches that are currently in use or in clinical development for patients with breast cancer prevent either estrogen synthesis or estrogen binding to nuclear estrogen receptors (ERs), thereby downregulating ER-mediated cell proliferation. The gene discussed is ESR1; the disease is breast cancer.